Dihydroartemisinin with minoxidil for female androgenetic alopecia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adult women with clinically diagnosed androgenetic alopecia will receive either daily oral dihydroartemisinin plus topical 5% minoxidil or topical 5% minoxidil alone for six months. Participants will attend the clinic once monthly for checkups and tests. The main outcome is change in terminal hair follicles in the vertex (top) scalp area. The comparison aims to determine whether adding dihydroartemisinin improves hair growth beyond minoxidil alone.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinically diagnosed with androgenetic alopecia (AGA)
* No pregnancy plans within the next 6 months

Exclusion Criteria:

* Patients who received systemic medications for hair loss within the past 2 months
* Use of topical medication for hair loss within the past 2 weeks
* Pregnancy or lactation
* Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.

Where it's running

• Zhongshan Hospital Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Jingjing JIANG, MD, PhD — Fudan University
• Study coordinator: Lujuan GAO, MD, PhD
• Email: gao.lujuan@zs-hospital.sh.cn
• Phone: 86-021-64041990

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Exosome therapy for male pattern baldness

  This trial tests whether injecting hUCMSC-derived exosomes into the scalp can promote hair regrowth in men with androgenetic alopecia, compared with a placebo.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07693244

• Multi-omics view of androgenetic alopecia in scalp tissue

  This study tests a multi-omics approach to understand hair follicle biology in men with androgenetic alopecia by comparing affected and healthy scalp tissue.

  Recruiting The First Affiliated Hospital of Xinxiang Medical College · Xinxiang, Henan · NCT07603544

• VENEZE peptide hair serum versus 2% topical minoxidil for androgenetic alopecia

  This trial tests if VENEZE peptide hair serum helps adults with androgenetic alopecia grow thicker, denser hair compared with 2% topical minoxidil.

  Recruiting at 2 sites Institute of Dermatology, Thailand · Bangkok, Bangkok and 1 other locations · NCT07536100

• Topical Lactobacillus reuteri for hair loss due to androgenetic alopecia

  This trial will test whether applying a topical Lactobacillus reuteri solution can increase hair count and improve hair quality in adults (18–60) with androgenetic alopecia over 12 months.

  Recruiting Phase 2 Shenzhen People's Hospital · Shenzhen, Guangdong · NCT07370519

• OLX72021 for men with male-pattern hair loss

  This research will test whether OLX72021 is safe and may help men aged 18 to 59 with mild to moderate male-pattern hair loss.

  Recruiting Phase 1/2 Olix Pharmaceuticals, Inc. · Botany, New South Wales and 7 other locations · NCT07327359

• ABS-201 for improving hair growth in healthy adults and people with androgenetic alopecia

  This trial will test whether ABS-201 is safe and helps hair grow in healthy adults and in men and women with androgenetic alopecia.

  Recruiting at 5 sites Phase 1/2 Absci Pty Ltd. · Sydney, New South Wales and 4 other locations · NCT07317544

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.